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In a recent issue of Nature, Hsu and colleagues report that oncogenic MYC activation is synthetic lethal with
inhibition of the core spliceosome, because MYC-driven growth and increased transcription leave tumors
dependent on pre-mRNA processing for survival. As direct targeting of MYC has remained elusive, synthetic
lethal strategies are attractive.MYC (c-MYC) is one of the most
commonly deregulated genes in cancers.
Although it has been heavily studied for
over three decades, attempts to pharma-
cologically inhibit MYC directly have re-
mained largely ineffective. Challenges
drugging MYC have raised interest in
finding drug targets that are synthetic le-
thal with MYC activation. MYC is a tran-
scription factor that dimerizes with its
partner MAX to drive transcription. By
increasing transcription through the relief
of RNA polymerase II pausing and selec-
tive gene activation, oncogenic MYC
drives the expression of a broad number
of genes with diverse functions, resulting
in an increase in cell biomass (Kress
et al., 2015). Through its unique ability to
activate Pol I, Pol II, and Pol III transcrip-
tion, MYC promotes ribosome synthesis
through the upregulation of rRNAs and ri-
bosomal proteins. MYC also stimulates
protein production through the upregula-
tion of cap dependent translation machin-
ery. Additionally, MYC drives expression
ofmetabolic enzymes to reprogrammeta-
bolism to provide cellular building blocks
to support increased cell biomass and
growth (Stine et al., 2015).
However, a perhaps underappreciated
step between MYC-driven transcription
and a subsequent increase in cell mass
is the mRNA processing required to
convert pre-mRNAs to mature mRNAs.
While the acquisition of increased
numbers of introns over the course of
evolution has allowed for greater tran-
scriptome complexity through alternative
splicing, introns must be removed to
ensure mRNA processing and stability.
Themammalian core spliceosome, a ribo-
nucleoprotein complex involving >130
proteins, is required for the processingof pre-mRNA to mature mRNA. When
introns are retained, mRNA processing
is inhibited and mRNA stability is
compromised.
A link between MYC and the regulation
of RNA processing enzymes has begun to
emerge. MYC regulation of HNRNP pro-
teins can control pyruvate kinase (PKM1
versus PKM2) alternative splicing (David
et al., 2010). Koh et al. (2015) recently
found that MYC-driven lymphomagenesis
upregulated genes required for produc-
tion of small nuclear ribonucleoprotein
particles (snRNPs), including Prmt5.
While loss of one copy of Prmt5 pro-
longed survival in the MYC-driven lym-
phoma model, ex vivo deletion of Prmt5
caused changes in mRNA processing
and resulted in cell cycle arrest and
apoptosis.
Hsu et al. (2015) have now built upon
these studies to show that targeting the
core spliceosome is a promising strategy
for treating MYC-driven cancers. Using a
genome-wide screen for genes whose
depletion is synthetic lethal with MYC
activation, the authors selected BUD31
as a candidate for further study. Detailed
studies showed that BUD31 interacts
with several parts of the core spliceosome
and is required for spliceosome catalytic
activity. Depletion of BUD31 has a much
stronger effect in MYC-activated cells
than control cells. Further, SD6-mediated
pharmacological inhibition of the core
spliceosome (Lagisetti et al., 2013) or
knockdown of other core spliceosome
factors (SF3B1, U2AF1, EFTUD2) also
showed synthetic lethality with MYC
activation.
Unlike the lymphoma model used by
Koh et al. (2015), MYC hyperactivation
did not upregulate the expression of spli-Cancer Cell 28ceosome proteins in the human mam-
mary epithelial cell (HMEC) model despite
upregulation of total cellular mRNA (Hsu
et al., 2015). The authors hypothesized
that increased transcription without upre-
gulation of spliceosome components
may stress the splicing system. RNA-
seq analysis was then used to test the
relationship between MYC activation,
BUD31 depletion, and pre-mRNA pro-
cessing. Depletion of BUD31 in conjunc-
tion with MYC activation greatly exacer-
bated intron retention compared to
depletion of BUD31 in the absence of
MYC activation. In fact, 42% (2,848 of
6,861) of the genes examined showed a
significant increase in intron retention
when BUD31 was depleted during MYC
activation. Consistent with decreased
mRNA processing and stability, depletion
of BUD31 following the inhibition of tran-
scription caused a large depletion of poly-
adenylated mRNA in MYC-activated cells
compared to controls. Targeted studies of
genes showing retained introns also indi-
cated that these genes show decreased
mRNA processing and stability. Gene
Ontology analysis showed that genes
with increased intron retention were
involved in a large number of critical
cellular functions, perhaps underlying
the induction of apoptosis following the
inhibition of the core spliceosome during
MYC activation.
The authors then sought to expand their
observations to additional models. Using
a panel of breast cancer cell lines, they
found that sensitivity to depletion of the
core spliceosome correlated with MYC
dependence. Breast cancer lines of
the basal subtype, which are highly MYC
dependent, were particularly sensitive
to core spliceosome depletion. Studies, October 12, 2015 ª2015 Elsevier Inc. 405
Figure 1. The BUD31 Dependent Core Spliceosome Catalyzes the Removal of Introns from
pre-mRNA
MYC activation increases transcription, causing dependence on the core spliceosome. Core spliceosome
inhibition causes increases intron retention resulting in apoptosis in MYC activated cells but not in cells
lacking MYC activation.
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tic triple-negative breast cancer MDA-
MB-231-LM2 cell line, which displayed
decreased proliferation and increased
caspase 3 cleavage following BUD31
depletion in vitro. In an in vivo cell compe-
tition assay, cells expressing inducible
shRNA targeting BUD31 or core spliceo-
some factor SF3B1 were found to be
depleted from xenografts compared to
control shRNA (Figure 1). Additionally,
cells expressing shRNA targeting BUD31
were not detectable among those cells
metastasizing to the lung. Similarly, SD6
treatment decreased the MDA-MB-231-
LM2 xenograft size and lung metastasis.
These observations suggest that MYC-
driven cancer cells depend on the core
spliceosome for tumor growth andmetas-
tasis in vivo.
This work, showing synthetic lethality
between MYC activation and core spli-
ceosome inhibition, is not the only
study suggesting mRNA processing
and splicing as a potential therapeutic406 Cancer Cell 28, October 12, 2015 ª2015target. Components of the spliceosome
(including SF3B1 and U2AF1) are recur-
rently mutated in some cancer types
(Yoshida et al., 2011). Other studies have
identified spliceosome components in
cancer as therapeutic targets using
screens (Adler et al., 2014; Hubert et al.,
2013; Quidville et al., 2013). The targeting
of the spliceosome as an anti-cancer ther-
apy would be aided by further study of
SD6 and the optimization and evaluation
of additional pharmacological spliceo-
some inhibitors currently under develop-
ment. The rational design of inhibitors
may be aided by recent progress in deter-
mining the structure of both yeast and
mammalian spliceosomes. Additional
studies will be required to determine the
efficacy of spliceosome inhibition in
MYC-driven tumors from other tissues of
origin. The differences in MYC-mediated
upregulation of spliceosome components
between the lymphoma mouse model
(Koh et al., 2015) and human breast can-
cer cell lines (Hsu et al., 2015) suggestsElsevier Inc.that there may be variability in spliceo-
some stress and the inhibition response
between tumors.
Despite intense study, MYC has proven
very difficult to drug due to its pleiotropic
effects. Bromodomain inhibitors have
been proposed as an anti-MYC therapy
because they can reduce MYC expres-
sion. However, the unchecked cell growth
and proliferation driven by oncogenic
MYC leaves cancer cells vulnerable to
the inhibition of some cellular processes.
Oncogenic MYC activation has been
shown to be synthetic lethal with inhibition
of translation, cell cycle, metabolism, and
cell signaling. Now the spliceosome takes
its place among these synthetic lethal
targets. Although synthetic lethal ap-
proaches are cause for excitement, bio-
markers will be needed to help identify
which tumors will respond to different
synthetic lethal therapeutic approaches.REFERENCES
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